PNTG vs. INNV, TALK, DCGO, WGS, SHCR, USPH, PRVA, LFST, ATXS, and ABSI
Should you be buying The Pennant Group stock or one of its competitors? The main competitors of The Pennant Group include InnovAge (INNV), Talkspace (TALK), DocGo (DCGO), GeneDx (WGS), Sharecare (SHCR), U.S. Physical Therapy (USPH), Privia Health Group (PRVA), LifeStance Health Group (LFST), Astria Therapeutics (ATXS), and Absci (ABSI). These companies are all part of the "medical" sector.
InnovAge (NASDAQ:INNV) and The Pennant Group (NASDAQ:PNTG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.
InnovAge has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, The Pennant Group has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500.
InnovAge currently has a consensus target price of $6.50, suggesting a potential upside of 62.50%. The Pennant Group has a consensus target price of $18.75, suggesting a potential downside of 8.71%. Given The Pennant Group's higher possible upside, analysts plainly believe InnovAge is more favorable than The Pennant Group.
In the previous week, InnovAge had 3 more articles in the media than The Pennant Group. MarketBeat recorded 7 mentions for InnovAge and 4 mentions for The Pennant Group. The Pennant Group's average media sentiment score of 0.26 beat InnovAge's score of -0.22 indicating that InnovAge is being referred to more favorably in the media.
The Pennant Group has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
The Pennant Group received 32 more outperform votes than InnovAge when rated by MarketBeat users. Likewise, 43.84% of users gave The Pennant Group an outperform vote while only 0.00% of users gave InnovAge an outperform vote.
The Pennant Group has a net margin of 2.46% compared to The Pennant Group's net margin of -4.38%. InnovAge's return on equity of 12.78% beat The Pennant Group's return on equity.
12.3% of InnovAge shares are owned by institutional investors. Comparatively, 85.9% of The Pennant Group shares are owned by institutional investors. 0.4% of InnovAge shares are owned by insiders. Comparatively, 5.8% of The Pennant Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
The Pennant Group beats InnovAge on 14 of the 18 factors compared between the two stocks.
Get The Pennant Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PNTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PNTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Pennant Group Competitors List
Related Companies and Tools
